- 同花顺特色产品
- 〈高级诊股〉 全方位深度分析，提供明确投资建议
- 短期趋势：
前期的强势行情已经结束，投资者及时卖出股票为为宜。
- 中期趋势：
-
- 长期趋势：
已有501家主力机构披露2024-06-30报告期持股数据，持仓量总计12.81亿股，占流通A股72.39%
- 波段诊断：
-
技术面诊股
平均成本
近期的平均成本为58.78元。
[{"text":"\u5e73\u5747\u6210\u672c","value":"58.78","date":1732175517,"color":"0x9f0ba1"}]
市场表现
过去10个交易日，该股走势接近大盘，接近行业平均水平。
[{"date":"2024.11.22","stock":"-2.44","trade":"-3.81","ind":"-3.52"},{"date":"2024.11.21","stock":"0.07","trade":"0.44","ind":"-0.07"},{"date":"2024.11.20","stock":"0.42","trade":"1.98","ind":"0.78"},{"date":"2024.11.19","stock":"0.47","trade":"1.11","ind":"1.90"},{"date":"2024.11.18","stock":"0.03","trade":"-1.71","ind":"-1.91"},{"date":"2024.11.15","stock":"-0.86","trade":"-2.21","ind":"-2.62"},{"date":"2024.11.14","stock":"-1.21","trade":"-2.33","ind":"-2.83"},{"date":"2024.11.13","stock":"-0.12","trade":"-1.37","ind":"0.40"},{"date":"2024.11.12","stock":"0.25","trade":"1.95","ind":"-0.65"},{"date":"2024.11.11","stock":"-0.84","trade":"0.61","ind":"2.03"},{"date":"2024.11.08","stock":"-0.64","trade":"-0.12","ind":"-0.66"},{"date":"2024.11.07","stock":"4.01","trade":"3.71","ind":"2.44"},{"date":"2024.11.06","stock":"-0.05","trade":"-0.03","ind":"-0.35"},{"date":"2024.11.05","stock":"1.40","trade":"1.93","ind":"3.22"},{"date":"2024.11.04","stock":"0.78","trade":"1.87","ind":"1.99"},{"date":"2024.11.01","stock":"0.63","trade":"-1.05","ind":"-1.28"},{"date":"2024.10.31","stock":"-1.47","trade":"-0.21","ind":"0.57"},{"date":"2024.10.30","stock":"0.28","trade":"-0.14","ind":"-0.12"},{"date":"2024.10.29","stock":"-0.88","trade":"-2.39","ind":"-1.33"},{"date":"2024.10.28","stock":"1.50","trade":"3.12","ind":"0.62"},{"date":"2024.10.25","stock":"0.46","trade":"0.66","ind":"1.71"}]
云南白药,深证成指,中药指数
压力支撑
该股压力位为58.68元，支撑位为57.75元。
[{"text":"\u538b\u529b\u4f4d","value":"58.68","date":1732204800,"color":"0x9f0ba1"},{"text":"\u652f\u6491\u4f4d","value":"57.75","date":1732204800,"color":"0x0b52a1"}]
多空趋势
macd
kdj
boll
asi
bias
rsi
wr
vr
资金面诊股
诊断结果：2.6资金面打败了22%的股票
主力控盘前10的股票
行业资金
中药行业， 近5日资金流出较多，不建议投资者关注该行业的个股。
更新时间：11月22日 17:42
| 机构今日流向(万元) | -4755.42 | 机构5日流向(万元) | -6641.38 |
| 机构10日流向(万元) | -18968.55 | 机构20日流向(万元) | -25082.99 |
机构持仓
2024-06-30 与 2023-12-31 相比，主力机构持仓量增加1095.31万股，其中基金净减仓47家，主力净增仓110家，请投资者中长期谨慎为宜。
截止2024-06-30，共501家主力机构（基金493家，QFII1家，一般法人6家，社保基金1家），持仓量总计128095.49万股，占流通A股72.39%
其中，基金持仓与2023-12-31相比：
增仓：96家 ，增持 1888.91万股
减仓：143家 ，减持 586.99万股
新出现在主力名单中：215家 ，持有2894.15万股
从主力名单中消失：105家 ，原持有3296.42万股
其中，基金持仓与2023-12-31相比：
增仓：96家 ，增持 1888.91万股
减仓：143家 ，减持 586.99万股
新出现在主力名单中：215家 ，持有2894.15万股
从主力名单中消失：105家 ，原持有3296.42万股
消息面诊股
诊断结果：6.3消息面打败了89%的股票
今日有利好新闻的公司
近期该股消息面总体多空平衡，没有较强的利好或利空趋势。
更多>>个股资讯
- 行业周报|中药指数跌-2.08%, 跑输上证指数0
2024-11-22 - 云南白药：11月21日获融资买入3638.88万元
2024-11-22 - 云南白药：11月20日获融资买入4755.52万元
2024-11-21 - 核医疗产业加速推进 人才与监管难题待解
2024-11-21 - 招商证券：维持云南白药“增持”评级，药品主业有望实
2024-11-19 - 62个独家中成药销售额合计超过170亿，片仔癀、复
2024-11-19 - 7家A股药企市值超千亿元，包括迈瑞医疗、恒瑞医药、
2024-11-19 - 云南白药：11月18日获融资买入5451.47万元
2024-11-19 - 云南白药集团中央研究院举办第十一期“焕章论坛”：癌
2024-11-18 - 云南白药每10股派12.13元 股权登记日为11月
2024-11-18
消息列表
| 一般消息 | 股东大会 | 临时股东大会 | 2024-10-30 |
| 利好 | 分红转增 | 10派12.13元(含税) | 2024-10-30 |
| 一般消息 | 分红转增 | 不分配不转增 | 2024-08-27 |
| 一般消息 | 高管变动 | 因个人职业发展规划调整原因 | 2024-08-26 |
| 一般消息 | 募资投向 | 公司购买资产 | 2024-06-29 |
| 一般消息 | 高管变动 | 因达到法定退休年龄 | 2024-06-11 |
| 一般消息 | 高管变动 | 因工作调整 | 2024-05-24 |
| 一般消息 | 重大事项 | 公司股东股份解押 | 2024-05-18 |
| 一般消息 | 重大事项 | 关联交易 | 2024-04-24 |
| 利好 | 分红转增 | 10派20.77元(含税) | 2024-03-30 |
| 一般消息 | 重大事项 | 关联交易 | 2024-03-30 |
| 一般消息 | 高管变动 | 因工作变动 | 2024-03-28 |
| 一般消息 | 高管变动 | 因个人原因 | 2024-02-07 |
| 一般消息 | 重大事项 | 关联交易 | 2023-12-29 |
一年消息统计
| 所有消息 | 重大消息 | 非重大消息 | |
| 利好 | 2条 | 0条 | 2条 |
| 利空 | 0条 | 0条 | 0条 |
行业面诊股
诊断结果：6.1行业面打败了79%的股票
中药行业最新资金流向
近10日来该行业走势总体向下，接近大盘。最近120个交易日，机构评级以增持为主，认为该行业有一定投资价值。
行业走势
近10日来该行业走势总体向下，接近大盘。
[{"date":"2024.11.22","price":"-3.52","value":"-3.81"},{"date":"2024.11.21","price":"-0.07","value":"0.44"},{"date":"2024.11.20","price":"0.78","value":"1.98"},{"date":"2024.11.19","price":"1.90","value":"1.11"},{"date":"2024.11.18","price":"-1.91","value":"-1.71"},{"date":"2024.11.15","price":"-2.62","value":"-2.21"},{"date":"2024.11.14","price":"-2.83","value":"-2.33"},{"date":"2024.11.13","price":"0.40","value":"-1.37"},{"date":"2024.11.12","price":"-0.65","value":"1.95"},{"date":"2024.11.11","price":"2.03","value":"0.61"},{"date":"2024.11.08","price":"-0.66","value":"-0.12"},{"date":"2024.11.07","price":"2.44","value":"3.71"},{"date":"2024.11.06","price":"-0.35","value":"-0.03"},{"date":"2024.11.05","price":"3.22","value":"1.93"},{"date":"2024.11.04","price":"1.99","value":"1.87"},{"date":"2024.11.01","price":"-1.28","value":"-1.05"},{"date":"2024.10.31","price":"0.57","value":"-0.21"},{"date":"2024.10.30","price":"-0.12","value":"-0.14"},{"date":"2024.10.29","price":"-1.33","value":"-2.39"},{"date":"2024.10.28","price":"0.62","value":"3.12"},{"date":"2024.10.25","price":"1.71","value":"0.66"}]
深证成指,中药行业
行业排名
| 排名 | 股票名称 | 1月涨跌幅 | 5日涨跌幅 | 评分 |
|---|---|---|---|---|
| 1 | 启迪药业 | 35.75% | 7.99% | 4.5分 |
| 2 | 嘉应制药 | 25.04% | 2.98% | 4.5分 |
| 3 | 香雪制药 | 21.67% | -6.43% | 3.6分 |
| 4 | 康美药业 | 15.50% | -2.12% | 4.0分 |
| 5 | 千金药业 | 14.90% | 20.04% | 5.4分 |
| 6 | 佛慈制药 | 13.49% | 2.94% | 4.6分 |
| 8 | 吉林敖东 | 9.29% | 0.87% | 4.3分 |
| 10 | *ST吉药 | 8.02% | -10.18% | 3.9分 |
| 12 | 信邦制药 | 7.67% | 5.87% | 5.1分 |
| 14 | ST九芝 | 6.67% | -8.02% | 4.3分 |
| 16 | ST百灵 | 5.50% | -6.28% | 4.0分 |
| 18 | 维康药业 | 4.64% | -4.14% | 3.9分 |
| 20 | 佐力药业 | 2.72% | 2.85% | 5.1分 |
| 22 | 益佰制药 | 2.41% | -1.29% | 4.0分 |
| 24 | 同仁堂 | 1.23% | -3.61% | 4.3分 |
| 26 | 太极集团 | 0.94% | -6.43% | 3.9分 |
| 28 | 汉森制药 | 0.49% | 0.32% | 4.8分 |
| 30 | 昆药集团 | -0.34% | -3.28% | 4.6分 |
| 32 | 康缘药业 | -0.76% | -4.16% | 4.2分 |
| 34 | 亚宝药业 | -0.98% | -0.98% | 4.8分 |
| 36 | 葵花药业 | -1.52% | -1.48% | 3.6分 |
| 38 | 白云山 | -1.65% | -2.87% | 4.8分 |
| 40 | 陇神戎发 | -1.84% | -1.52% | 4.0分 |
| 42 | 仁和药业 | -2.01% | -1.68% | 4.0分 |
| 44 | 红日药业 | -3.21% | -3.21% | 3.6分 |
| 46 | 华润三九 | -3.69% | -5.01% | 4.9分 |
| 48 | 桂林三金 | -3.96% | -1.82% | 4.8分 |
| 50 | 东阿阿胶 | -4.23% | -3.05% | 4.8分 |
| 52 | 长药控股 | -4.46% | -8.02% | 3.5分 |
| 54 | 莱茵生物 | -4.80% | -3.61% | 4.3分 |
| 56 | 华神科技 | -4.97% | 0.96% | 4.4分 |
| 58 | 珍宝岛 | -5.18% | -3.32% | 4.7分 |
| 60 | 贵州三力 | -5.53% | -2.92% | 5.0分 |
| 62 | 特一药业 | -6.33% | -1.13% | 3.7分 |
| 64 | 济川药业 | -7.11% | -5.56% | 4.5分 |
| 66 | 广誉远 | -8.56% | -4.06% | 4.0分 |
| 68 | 恩威医药 | -10.63% | -5.37% | 3.7分 |
| 70 | 方盛制药 | -13.97% | -5.77% | 4.7分 |
| 72 | - | -21.92% | -3.26% | 分 |
行业评级
最近120个交易日，机构评级以增持为主，认为该行业有一定投资价值。
- 综合评级
| 研究机构 | 评级日期 | 最新评级 | 上次评级 |
| 中信证券 | 2012-09-10 | 增持 | 增持 |
| 招商证券 | 2012-09-08 | 增持 | 增持 |
| 航天证券 | 2012-09-06 | 增持 | - |
| 中银国际 | 2012-09-05 | 增持 | - |
| 齐鲁证券 | 2012-09-05 | 增持 | - |
更多>>行业资讯
- 2012-09-13亿利能源股权质押登记
- 2012-09-13太极集团修改《公司章程》
- 2012-09-13人福医药获得国家补助资金
- 2012-09-13常山药业：归还暂时用于补充流动资金的闲置募集资金
- 2012-09-13贵州百灵：公司与济南百诺医药科技开发有限公司签订技
- 2012-09-13振东制药山西省第三建筑工程公司承建山西振东泰盛制药
- 2012-09-13双成药业：战略合作框架协议进展
- 2012-09-13佛慈制药：签订推荐恢复上市、委托代办股份转让协议
- 2012-09-13昊海生科IPO资产被疑是大江股份上市募投项目
- 2012-09-13泰格医药涨势猛 业务有望快速扩张
基本面诊股
[ 截止日期：2024-09-30 ]公司经营
盈利能力：较强，高于行业平均，建议加强关注，两项指标的行业排名分别为 16/117 ， 63/117。
[{"date":"2024-09-30","value":"10.76","vol":"3.01"},{"date":"2024-06-30","value":"8.05","vol":"1.51"},{"date":"2024-03-31","value":"4.18","vol":"1.57"},{"date":"2023-12-31","value":"10.45","vol":"1.32"},{"date":"2023-09-30","value":"10.52","vol":"-36.03"}]
| 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | |
|---|---|---|---|---|---|
| 净资产收 益率(%) |
10.76 | 8.05 | 4.18 | 10.45 | 10.52 |
| 行业(%) | 3.01 | 1.51 | 1.57 | 1.32 | -36.03 |
该指标值越高，盈利能力越强，行业排名越靠前。
[{"date":"2024-09-30","value":"28.40","vol":"52.26"},{"date":"2024-06-30","value":"29.30","vol":"52.53"},{"date":"2024-03-31","value":"29.98","vol":"52.91"},{"date":"2023-12-31","value":"26.51","vol":"53.66"},{"date":"2023-09-30","value":"27.37","vol":"54.60"}]
| 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | |
|---|---|---|---|---|---|
| 销售毛利 率(%) |
28.40 | 29.30 | 29.98 | 26.51 | 27.37 |
| 行业(%) | 52.26 | 52.53 | 52.91 | 53.66 | 54.60 |
该指标值越高，盈利能力越强，行业排名越靠前。
成长能力：很强，位居行业前列,建议强烈关注，两项指标的行业排名分别为 20/117 ， 24/117。
[{"date":"2024-09-30","value":"0.76","vol":"-4.89"},{"date":"2024-06-30","value":"0.72","vol":"-4.85"},{"date":"2024-03-31","value":"2.49","vol":"-2.72"},{"date":"2023-12-31","value":"7.19","vol":"3.91"},{"date":"2023-09-30","value":"10.30","vol":"6.61"}]
| 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | |
|---|---|---|---|---|---|
| 营业收入同 比增长率(%) |
0.76 | 0.72 | 2.49 | 7.19 | 10.30 |
| 行业(%) | -4.89 | -4.85 | -2.72 | 3.91 | 6.61 |
该指标值越高，成长能力越强，行业排名越靠前。
[{"date":"2024-09-30","value":"4.93","vol":"-1.06"},{"date":"2024-06-30","value":"12.76","vol":"-20.25"},{"date":"2024-03-31","value":"12.12","vol":"-11.34"},{"date":"2023-12-31","value":"36.41","vol":"-18.78"},{"date":"2023-09-30","value":"78.90","vol":"9.62"}]
| 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | |
|---|---|---|---|---|---|
| 净利润同比 增长率(%) |
4.93 | 12.76 | 12.12 | 36.41 | 78.90 |
| 行业(%) | -1.06 | -20.25 | -11.34 | -18.78 | 9.62 |
该指标值越高，成长能力越强，行业排名越靠前。
营运能力：很强，位居行业前列,建议强烈关注，两项指标的行业排名分别为 10/117 ， 6/117。
[{"date":"2024-09-30","value":"0.55","vol":"0.36"},{"date":"2024-06-30","value":"0.38","vol":"0.25"},{"date":"2024-03-31","value":"0.19","vol":"0.13"},{"date":"2023-12-31","value":"0.73","vol":"0.53"},{"date":"2023-09-30","value":"0.56","vol":"0.39"}]
| 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | |
|---|---|---|---|---|---|
| 总资产周 转率(次) |
0.55 | 0.38 | 0.19 | 0.73 | 0.56 |
| 行业(次) | 0.36 | 0.25 | 0.13 | 0.53 | 0.39 |
该指标值越高，营运能力越强，行业排名越靠前。
[{"date":"2024-09-30","value":"3.41","vol":"1.77"},{"date":"2024-06-30","value":"2.33","vol":"1.21"},{"date":"2024-03-31","value":"1.20","vol":"0.65"},{"date":"2023-12-31","value":"3.98","vol":"2.83"},{"date":"2023-09-30","value":"2.89","vol":"2.04"}]
| 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | |
|---|---|---|---|---|---|
| 存货增长 率(次) |
3.41 | 2.33 | 1.20 | 3.98 | 2.89 |
| 行业(次) | 1.77 | 1.21 | 0.65 | 2.83 | 2.04 |
该指标值越高，营运能力越强，行业排名越靠前。
现金流能力：数据暂时不全，请后续关注
[{"date":"2024-09-30","value":"8.58","vol":"5.27"},{"date":"2024-06-30","value":"28.25","vol":"9.55"},{"date":"2024-03-31","value":"4.89","vol":"0.64"},{"date":"2023-12-31","value":"9.69","vol":"19.92"},{"date":"2023-09-30","value":"3.60","vol":"7.50"}]
| 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | |
|---|---|---|---|---|---|
| 现金流量净额/营业收入 | 8.58 | 28.25 | 4.89 | 9.69 | 3.60 |
| 行业 | 5.27 | 9.55 | 0.64 | 19.92 | 7.50 |
该指标值越高，现金流能力越强，行业排名越靠前。
[{"date":"2024-09-30","value":"","vol":"0.00"},{"date":"2024-06-30","value":"1.40","vol":"1.34"},{"date":"2024-03-31","value":"","vol":"0.00"},{"date":"2023-12-31","value":"1.54","vol":"1.43"},{"date":"2023-09-30","value":"","vol":"0.00"}]
| 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | |
|---|---|---|---|---|---|
| 资本支出／折旧和摊销 | - | 1.40 | - | 1.54 | - |
| 行业 | 0.00 | 1.34 | 0.00 | 1.43 | 0.00 |
该指标值越低，现金流能力越强，行业排名越靠前。
短期偿债能力：较强，高于行业平均，建议加强关注，两项指标的行业排名分别为 25/117 ， 42/117。
[{"date":"2024-09-30","value":"2.69","vol":"3.23"},{"date":"2024-06-30","value":"2.64","vol":"2.95"},{"date":"2024-03-31","value":"2.77","vol":"2.98"},{"date":"2023-12-31","value":"2.85","vol":"2.83"},{"date":"2023-09-30","value":"2.88","vol":"2.95"}]
| 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | |
|---|---|---|---|---|---|
| 流动比率 |
2.69 | 2.64 | 2.77 | 2.85 | 2.88 |
| 行业 | 3.23 | 2.95 | 2.98 | 2.83 | 2.95 |
该指标值越接近2，短期偿债能力越强，行业排名越靠前。
[{"date":"2024-09-30","value":"2.06","vol":"2.43"},{"date":"2024-06-30","value":"2.05","vol":"2.24"},{"date":"2024-03-31","value":"2.17","vol":"2.29"},{"date":"2023-12-31","value":"2.06","vol":"2.15"},{"date":"2023-09-30","value":"2.06","vol":"2.23"}]
| 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | |
|---|---|---|---|---|---|
| 速动比率 |
2.06 | 2.05 | 2.17 | 2.06 | 2.06 |
| 行业 | 2.43 | 2.24 | 2.29 | 2.15 | 2.23 |
该指标值越接近1，短期偿债能力越强，行业排名越靠前。
长期偿债能力：尚可，接近行业平均，可适当关注，两项指标的行业排名分别为 39/117 ， 43/117。
[{"date":"2024-09-30","value":"27.10","vol":"34.45"},{"date":"2024-06-30","value":"27.55","vol":"35.22"},{"date":"2024-03-31","value":"26.85","vol":"34.41"},{"date":"2023-12-31","value":"25.80","vol":"34.63"},{"date":"2023-09-30","value":"25.21","vol":"34.12"}]
| 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | |
|---|---|---|---|---|---|
| 资产负债 率(%) |
27.10 | 27.55 | 26.85 | 25.80 | 25.21 |
| 行业(%) | 34.45 | 35.22 | 34.41 | 34.63 | 34.12 |
该指标值越接近50%，长期偿债能力越强，行业排名越靠前。
[{"date":"2024-09-30","value":"0.37","vol":"3.07"},{"date":"2024-06-30","value":"0.38","vol":"1.58"},{"date":"2024-03-31","value":"0.37","vol":"0.95"},{"date":"2023-12-31","value":"0.35","vol":"0.86"},{"date":"2023-09-30","value":"0.34","vol":"0.59"}]
| 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | |
|---|---|---|---|---|---|
| 产权比率 (%) |
0.37 | 0.38 | 0.37 | 0.35 | 0.34 |
| 行业(%) | 3.07 | 1.58 | 0.95 | 0.86 | 0.59 |
该指标值越高，长期偿债能力越强，行业排名越靠前。
机构评级
最近60个交易日，机构评级以增持为主，认为该股票有一定投资价值。
| 研究机构 | 评级日期 | 最新评级 | 上次评级 |
| 海通证券 | 2024-11-18 | 增持 | 增持 |
| 招商证券 | 2024-11-18 | 增持 | 增持 |
| 中信建投证券 | 2024-11-07 | 买入 | 买入 |
| 兴业证券 | 2024-11-06 | 增持 | |
| 国泰君安 | 2024-11-04 | 买入 | 买入 |
| 西部证券 | 2024-11-01 | 增持 |
机构预测
机构预测该股2024年每股收益与前一年相同，长期投资价值一般。
[{"date":"2020","yellowRectValue":"55.16","blueLineValue":"","type":""},{"date":"2021","yellowRectValue":"28.04","blueLineValue":"","type":""},{"date":"2022","yellowRectValue":"30.01","blueLineValue":"","type":""},{"date":"2023","yellowRectValue":"40.94","blueLineValue":"","type":""},{"date":"2024","yellowRectValue":"45.63","blueLineValue":"2.55","type":"YC"}]